Advanced Search


Study ID Status Title Patient Level Data
116158 Terminated An open label study to evaluate the effects of ezogabine/retigabine added to existing anti-epileptic drug(s) on urinary voiding function in subjects with partial onset seizures Study Listed on
116160 Terminated A two part study to evaluate the safety, tolerability, and pharmacokinetics of GSK2251052 after single ascending dosesand repeat doses of IV GSK2251052 in healthy male Japanese and Caucasian subjects and a repeat dose study to evaluatesupratherapeutic doses of IV GSK2251052 in healthy volunteers
116170 Completed A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus Study Listed on
116174 Completed A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus
116181 Completed A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
116183 Recruiting A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies
116194 Active, not recruiting Immunogenicity and safety of GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b (DTPa-IPV/Hib) conjugate vaccine
116197 Completed A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE (LATITUDE)-TIMI 60. Study Listed on
116208 Completed Population based surveillance to estimate the burden of herpes zoster and post-herpetic neuralgia in Italy
116213 Withdrawn A randomized, double-blind, placebo-controlled, repeat dose, 2-period incomplete block crossover safety and pharmacokinetic study of umeclidinium in adolescent asthma subjects
116216 Completed An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers Study Listed on
116235 Terminated Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL study)
116236 Completed A two-part, randomised, placebo-controlled study to investigatethe safety, tolerability, pharmacokinetics and pharmacodynamicsof single doses of inhaled GSK1995057 in healthy subjects
116239 Completed An observational cohort study to assess the risk of autoimmune diseases in adolescent and young adult women aged 9 to 25 years exposed to Cervarix® in the United Kingdom
116246 Completed A multicenter, randomized, evaluator-masked, parallel-group, non-treatment-controlled study followed by an open-label study to evaluate efficacy and safety of GSK1358820 (botulinum toxin type A) in patients with strabismus
116247 Withdrawn An open-label, single centre, parallel group study to evaluate the safety and pharmacokinetics of single oral doses of retigabine extended release (XR) formulation in healthy adult Japanese and Caucasian subjects
116259 Completed Observational database study on the incidence of intussusception in children aged less than 12 months in Japan
116265 Active, Not Recruiting PGx432 evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics: meta-analysis of Phase 1 studies ING111521, ING111603, ING111604, ING112934, ING113068, ING113096, ING114005, ING114819, ING113099
116266 Terminated A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects Study Listed on
116268 Completed Comparison of Maraviroc to Efavirenz, Atazanavir, Darunavir, Lopinavir/Ritonavir, and Raltegravir for Treatment-Naïve Persons with CCR5-Positive HIV-1 in Canada
116273 Completed Burden of Influenza in the United Kingdom, 1996-2008
116276 Completed Utilization of Rosiglitazone in Triple Therapy and Insulin Combinations, and Estimated Rates of Adverse Events in Rosiglitazone Recipients in Canada, 2004-2010
116281 Completed Persistence and Compliance among United States patients with advanced Renal Cell Carcinoma receiving treatment with Pazopanib
116287 Completed An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of KIVEXA(abacavir/lamivudine) administered in Korean patients according to the prescribing information
116288 Completed The effect of dutasteride (0.5 mg/day) on prostate cancer risk reduction using three randomized controlled trials; A set of meta-analyses.



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.